SORRENTO THERAPEUTICS AND VIRALCLEAR ENTER INTO AGREEMENT TO EXPLORE THE COMBINATION OF ANTIBODY AND ANTIVIRAL ASSETS AGAINST COVID-19 September 30, 2020
ViralClear Expands Ongoing Phase 2 Trial Size for its Oral Anti-Viral for the Treatment of COVID-19, Expands Trial Locations and Appoints Contract Manufacturing Organization to Manufacture Phase 3 Supplies of Merimepodib Oral Solution September 22, 2020
Reminder: ViralClear to Host Conference Call and Webcast on September 22, 2020 to Discuss Phase 2 Human Trial of AntiViral Merimepodib Oral Solution for Treatment of COVID-19 September 21, 2020
BioSig Releases PURE EP Study Abstract with Data Presented at European Society of Cardiology’s ‘ESC Congress 2020’ September 15, 2020
Reminder: BioSig to Host Conference Call and Webcast on September 15, 2020 to Discuss Unblinding of PURE EP Human Data September 14, 2020
ViralClear to Host Conference Call on September 22, 2020, to Discuss Phase 2 Human Trial of AntiViral Merimepodib Oral Solution for Treatment of COVID-19 September 9, 2020
BioSig to Host Conference Call on September 15, 2020 to Discuss Unblinding of PURE EP Human Data September 2, 2020
Infectious Diseases Expert Prof. Angus Dalgleish Joins ViralClear’s Scientific Advisory Board August 6, 2020
